Safety first
Educational only. Not medical advice. HRT side effects and risks vary by formulation, route, dose, and individual health history. If you experience signs of blood clots (leg swelling, chest pain, shortness of breath), stroke (sudden weakness, confusion, vision changes), or severe allergic reaction, seek emergency care immediately.
Overview
Every medication has side effects. HRT is no exception. But the risk conversation around HRT has been distorted by two decades of oversimplified fear since the WHI headlines. The result is that many women either avoid HRT entirely based on exaggerated risk perception, or take it without understanding the real risks that do exist and how they apply to their specific situation.
The truth is more nuanced than either camp suggests. HRT has real, documented risks. It also has real, documented benefits. The question is not “is HRT risky?” but “for me specifically, do the benefits outweigh the risks?” - and that question requires actual data, not headlines.
Key Takeaways
- Common adjustment side effects (breast tenderness, bloating, headache, mood changes) affect many women in the first 1 to 3 months and typically resolve with continued use or dose adjustment
- VTE risk is increased with oral estrogen but not significantly with transdermal estrogen. The route of administration matters
- Breast cancer risk depends on the type of HRT: estrogen-only therapy was not associated with increased risk in the WHI; combined therapy (specifically CEE + MPA) showed a small increase after 5+ years
- The absolute risk increase for breast cancer with combined HRT is approximately 8 additional cases per 10,000 women per year. This is less than the risk associated with obesity or regular alcohol consumption
- Cardiovascular risk depends on timing. HRT started within 10 years of menopause may be cardioprotective. Started later, it may increase risk
Common Adjustment Side Effects
These are typically temporary and manageable.
Breast tenderness. Common in the first 1-3 months, particularly with higher estrogen doses. Usually resolves as the body adjusts. If severe, dose reduction may help.
Bloating and fluid retention. Related to estrogen’s effect on sodium and water balance. Usually improves within the first few months.
Headache. Can occur during initial adjustment. Migraine sufferers should discuss this with their clinician, as the type of migraine matters for HRT safety (migraine with aura has different implications than migraine without aura).
Mood changes. Some women experience mood fluctuations during initial dose adjustment. If persistent or severe, the regimen may need modification. Worsening depression or new-onset anxiety should be reported promptly.
Nausea. More common with oral estrogen. Taking with food or switching to a transdermal route often resolves it.
Breakthrough bleeding. Expected during the first 3 to 6 months of continuous combined therapy. On cyclic regimens, withdrawal bleeding during the progestogen-free phase is by design. Bleeding that persists beyond 6 months, is heavy, or returns after stopping should be evaluated. See the dosing guide for details.
The Serious Risks - With Context
Venous thromboembolism (VTE). Oral estrogen increases VTE risk by approximately twofold compared to non-use. Transdermal estrogen does NOT significantly increase VTE risk based on multiple observational studies. For women with VTE risk factors, transdermal is strongly preferred. This is one of the most clinically important route-specific differences.
The WHI findings are more nuanced than the 2002 headlines suggest. See our WHI deep dive for the full picture, including age-stratified reanalysis and what the data actually shows for women starting HRT near menopause.
Stroke. A small increased risk was observed in the WHI, primarily with oral estrogen. The risk is concentrated in older women (over 60) and those starting HRT well past menopause. For women under 60 starting within 10 years of menopause, the stroke risk is minimal. Transdermal estrogen at standard doses does not appear to increase stroke risk.
Gallbladder disease. Oral estrogen increases gallbladder disease risk. Transdermal routes carry lower risk because they bypass first-pass liver metabolism.
When To Seek Immediate Care
Sudden leg swelling, warmth, or pain (especially one-sided) - possible DVT. Chest pain, shortness of breath, or coughing blood - possible PE. Sudden numbness, weakness, confusion, vision changes, or severe headache - possible stroke. Heavy or prolonged vaginal bleeding. Severe abdominal pain. Signs of allergic reaction (swelling, difficulty breathing).
When To Contact Your Clinician (Not Emergency)
Breast tenderness that does not resolve after 3 months. Persistent headaches or new migraine pattern. Mood changes that are worsening rather than improving. Breakthrough bleeding beyond 6 months on continuous therapy. Any new breast lump or changes.
Questions To Ask A Clinician
- What are the most important risks for me personally given my health history?
- Should I use transdermal rather than oral estrogen based on my risk profile?
- How does the type of progestogen you are prescribing affect my breast cancer risk?
- What side effects should I expect in the first 1-3 months, and which ones should prompt me to call you?
- How will you monitor for risks during treatment?